Table 1.

Results of analysis of changes in the relative levels of mRNA of LRRN3, MEF2C, SLC22A4, and P2RY12 genes in the peripheral blood of patients in early stages of PD (fold change relative to healthy control).

Gene	Patients with PD Who Did Not Receive Therapy	Patients with PD Who Received Therapy	Neurological Control
LRRN3	0.32 1 (0.18; 0.51) 2	0.50 (0.39; 0.56)	0.91 (0.62; 1.31)
MEF2C	2.56 (2.09; 2.74)	2.36 (1.84; 2.93)	3.14 (2.48; 3.75)
SLC22A4	3.26 (2.45; 4.14)	2.99 (1.93; 3.33)	2.34 (1.50; 3.04)
P2RY12	1.06 (0.85-1.33)	0.59 (0.54; 1.33)	0.91 (0.71; 1.08)

¹ Median, ² 25–75 percentiles. Values with p < 0.05 are shown in bold. The expression level in the control was set to 1.